Progress in Gynecologic Cancers with Antibody Drug Conjugates
Objective of evaluate: This text supplies a complete evaluate of antibody-drug conjugates (ADCs) beneath investigation in gynecologic cancers. The construction and performance of ADCs are reviewed with a deal with medical profit in addition to toxicity profiles.
Latest findings: A number of ADCs with varied goal antigens have been investigated in ovarian, cervical, and endometrial most cancers. ADCs have constantly demonstrated favorable security/tolerability profiles each as monotherapy and together remedy. In ovarian most cancers, response charges have ranged from 9 to 46% for monotherapy with response charges as excessive as 83% together remedy. In sufferers with cervical most cancers with progressive illness regardless of doublet remedy and bevacizumab, response charges as excessive as 24% have been noticed. ADCs characterize a quickly evolving area of focused remedy which have demonstrated notable medical profit each as monotherapy but additionally together remedy with an general favorable toxicity profile. With continued refinement of the goal biomarkers utilized, improved medical profit is more likely to be noticed.
Low seroprevalence of SARS-CoV-2 antibodies in a liver transplant cohort
Stable organ transplant recipients would possibly be at larger threat for acquisition and mortality on account of SARS-CoV-2. There isn’t a knowledge concerning SARS-CoV-2 seroprevalence amongst liver transplant (LT) recipients, and whether or not it’s totally different from that of the final inhabitants or different immunosuppressed teams. We evaluated the prevalence of IgG SARS-CoV-2 antibodies amongst LT recipients to estimate the frequency of asymptomatic SARS-CoV-2 an infection utilizing serological assays in our outpatient clinic. We performed a cross-sectional evaluation from Could 10th to October 26th 2020 of all grownup (>18 years) LT recipients that underwent a routine laboratory check for the outpatient clinic follow-up on the Hospital Universitari Vall d’Hebron (Barcelona) during which we included serological testing for SARS-CoV-2. 9 out of 294 LT recipients (3.1%) examined optimistic for anti-SARS-CoV-2 IgG antibodies.
5 of them (55.5%) had suffered clinically symptomatic SARS-CoV2 an infection confirmed by RT-PCR, 4 (44.4%) had offered suitable signs however with out microbiological affirmation and just one affected person (1/9, 11.1%) examined optimistic with none earlier symptom. SARS-CoV-2 seroprevalence amongst LT recipients in an space extremely affected by the pandemic is decrease than within the basic inhabitants in the identical space. These outcomes render the potential of asymptomatic an infection in LT recipients not possible.
Novel antibody cocktail concentrating on Guess v 1 quickly and sustainably treats birch allergy signs in a Part 1 examine
Background: The efficacy of an allergen-specific IgG cocktail to deal with cat allergy means that allergen-specific IgG could also be a significant protecting mechanism elicited by allergen immunotherapy.
Goal: Extending these findings, we examined a Guess v 1-specific antibody cocktail in birch-allergic topics.
Strategies: Part 1, randomized, double-blind, examine: Half-A, ascending doses of Guess v 1-specific antibody cocktail “REGN5713/14/15” (150-900 mg) in 32 wholesome adults; Half-B, single subcutaneous 900 mg dose or placebo in 64 birch-allergic topics. Complete nasal symptom rating (TNSS) response to titrated birch extract nasal allergen problem (NAC) and pores and skin prick check (SPT) with birch and alder allergen have been assessed at screening and days 8, 29, 57 and 113 (SPT solely); basophil activation checks (n=26) have been performed.
Outcomes: Single dose REGN5713/14/15 considerably diminished TNSS following birch NAC relative to baseline. Variations in TNSS AUC(0-1 hr) versus placebo (day 8: -1.17, P = .001; day 29: -1.18, P = .001; day 57: -0.85, P = .024) and titration SPT with birch distinction in AUC of imply wheal diameters versus placebo (all P < .001) have been sustained for ≥2 months; comparable outcomes noticed with alder SPT. REGN5713/14/15 was well-tolerated. Basophil responsiveness to birch-related allergens was considerably decreased in REGN5713/14/15-treated topics versus placebo on days 8, 57, and 113 (all P < .01).
Conclusion: Single dose REGN5713/14/15 was effectively tolerated and offered a speedy (1 week) and sturdy (2 months) discount in allergic signs after birch allergen NAC, probably providing a brand new paradigm for the remedy of birch allergy signs.
Transfusion-induced platelet antibodies and regulatory T cells in multiply transfused sufferers
Background: Platelet transfusion refractoriness (PTR) stays a tough drawback in sufferers requiring long-term platelet supportive care. Nonetheless, there are little knowledge on the frequency of platelet antibodies in multiply transfused Chinese language sufferers. Furthermore, the connection between peripheral regulatory T cells (Tregs) and PTR stays unclear.
Strategies: We retrospectively studied the frequency of alloimmunization towards platelet antigens in sufferers receiving a number of transfusions between 2013 and 2017. Monoclonal antibody solid-phase platelet antibody check (MASPAT) kits have been used to display screen for platelet antibodies earlier than every platelet transfusion. Peripheral Tregs and CD4+ CD25+ CD127– T cells have been detected by circulate cytometry, whereas reworking progress factor-beta (TGF-β) and interleukin (IL)-17 cytokines have been detected by enzyme-linked immunosorbent assay.
Outcomes: A complete of 399 sufferers who met the inclusion standards have been enrolled for the evaluation of platelet antibodies and refractoriness. Amongst these sufferers, 10 (2.5%) have been optimistic for platelet antibodies earlier than transfusion and 47 (11.8%) grew to become antibody-positive throughout the examine interval. The variety of alloimmunized sufferers was considerably greater in sufferers with hematological illness as in contrast with different illness teams (p < 0.05). Refractoriness and alloimmunization occurred in 77 (19.3%) and 22 (28.6%) sufferers, respectively. There have been no vital variations in CD4+ , CD8+ , and CD4+ CD25+ CD127– T cell numbers and plasma ranges of TGF-β1 and IL-17 between sufferers with PTR and the management group.
Conclusions: Refractoriness was frequent in sufferers present process a number of platelet transfusions (19.3%), with alloimmunization noticed in 28.6% of sufferers. Nonetheless, Tregs in peripheral blood might not play a key position in PTR.
Younger infants exhibit strong purposeful antibody responses and restrained IFN-γ manufacturing to SARS-CoV-2
Extreme COVID-19 seems uncommon in kids. That is surprising, particularly in younger infants, who’re susceptible to extreme illness attributable to different respiratory viruses. We consider convalescent immune responses in 4 infants beneath 3 months previous with confirmed COVID-19 who offered with delicate febrile sickness, alongside their dad and mom, and grownup controls recovered from confirmed COVID-19.
Though not statistically vital, in comparison with seropositive adults, infants have excessive serum ranges of IgG and IgA to SARS-CoV-2 spike protein with corresponding purposeful skill to dam SARS-CoV-2 mobile entry. Infants additionally exhibit strong saliva anti-spike IgG and IgA responses. Spike-specific IFN-γ manufacturing by toddler peripheral blood mononuclear cells seems restrained, however the frequency of spike-specific IFN-γ and/or TNF-ɑ producing T cells is comparable between infants and adults. On principal part evaluation, toddler immune responses seem distinct from their dad and mom. Sturdy purposeful antibody responses alongside restrained IFN-γ manufacturing might assist defend infants from extreme COVID-19.
Salivary IgA antibody to malondialdehyde-acetaldehyde associates with delicate periodontal pocket depth
Goal: Oxidized epitopes reminiscent of malondialdehyde-acetaldehyde (MAA) play an important position within the development of atherosclerosis by way of activation of the humoral immune response. The precise mechanism of the affiliation between atherosclerosis and periodontal illnesses shouldn’t be totally understood. The purpose of the present examine is to judge the affiliation of oral humoral immune response to oxidized epitopes with parameters of periodontal illness.
Supplies and strategies: The Parogene cohort encompass sufferers who’ve undergone coronary angiography on account of cardiac signs. On this examine, 423 sufferers have been randomly chosen for an in depth oral examination. Salivary Immunoglobulin A to oxidized epitopes and bacterial antigens was decided by chemiluminescence immunoassay.
Outcomes: In a binary logistic regression mannequin adjusted with periodontal illness confounders, periodontal pocket depth (PPD) 4-5 mm related to salivary IgA antibodies to MAA-LDL (p = 0.034), warmth shock protein 60 of Aggregatibacter actinomycetemcomitans (p = 0.045), Porphyromonas gingivalis (p = 0.045), A. actinomycetemcomitans (p = 0.005), P. intermedia (p = 0.020), and complete IgA (p = 0.003).
Conclusions: The present examine reveals the affiliation of salivary IgA to MAA-LDL with PPD 4-5 mm in a cohort of sufferers with continual coronary artery illness. Humoral immune cross-reactivation to oxidized epitopes such MAA-LDL may partly clarify the hyperlink of periodontitis with systemic illnesses.
 anti-LIF |
|||
| YF-PA12952 | Abfrontier | 50 ug | EUR 435.6 |
|
Description: Mouse polyclonal to LIF |
|||
 ELISA Kit) Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-b-48T | DL Develop | 48T | EUR 656.4 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids. |
|||
Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-b-96T | DL Develop | 96T | EUR 858 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids. |
|||
 ELISA Kit) Canine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-c-48T | DL Develop | 48T | EUR 632.4 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Canine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Canine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-c-96T | DL Develop | 96T | EUR 825.6 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Canine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
 ELISA Kit) Human Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-Hu-48T | DL Develop | 48T | EUR 456 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Human Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-Hu-96T | DL Develop | 96T | EUR 582 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
 ELISA Kit) Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-p-48T | DL Develop | 48T | EUR 656.4 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Porcine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids. |
|||
Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-p-96T | DL Develop | 96T | EUR 858 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Porcine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids. |
|||
 ELISA Kit) Rat Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-Ra-48T | DL Develop | 48T | EUR 609.6 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Rat Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| DLR-LIF-Ra-96T | DL Develop | 96T | EUR 793.2 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
|||
Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-b-48Tests | Reddot Biotech | 48 Tests | EUR 666 |
Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-b-96Tests | Reddot Biotech | 96 Tests | EUR 925.2 |
Canine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-c-48Tests | Reddot Biotech | 48 Tests | EUR 639.6 |
Canine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-c-96Tests | Reddot Biotech | 96 Tests | EUR 888 |
Human Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 440.4 |
Human Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 602.4 |
Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-p-48Tests | Reddot Biotech | 48 Tests | EUR 666 |
Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-p-96Tests | Reddot Biotech | 96 Tests | EUR 925.2 |
Rat Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 613.2 |
Rat Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RD-LIF-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 850.8 |
Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-b-48Tests | Reddot Biotech | 48 Tests | EUR 696 |
Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-b-96Tests | Reddot Biotech | 96 Tests | EUR 968.4 |
Canine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-c-48Tests | Reddot Biotech | 48 Tests | EUR 668.4 |
Canine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-c-96Tests | Reddot Biotech | 96 Tests | EUR 928.8 |
Human Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 459.6 |
Human Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 630 |
Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-p-48Tests | Reddot Biotech | 48 Tests | EUR 696 |
Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-p-96Tests | Reddot Biotech | 96 Tests | EUR 968.4 |
Rat Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 640.8 |
Rat Leukemia Inhibitory Factor (LIF) ELISA Kit |
|||
| RDR-LIF-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 890.4 |
 LIF, mouse |
|||
| MO16102 | Neuromics | 100 ug | EUR 810 |
 LIF, Mouse |
|||
| HY-P7084 | MedChemExpress | 50ug | EUR 639.6 |
 Rabbit Polyclonal antibody Anti-CRBN |
|||
| Anti-CRBN | ImmunoStep | 50 µg | EUR 418.8 |
 Anti-LIF Antibody |
|||
| A01400 | BosterBio | 100ug/vial | EUR 352.8 |
Anti-LIF Antibody |
|||
| PA1562 | BosterBio | 100ug/vial | EUR 352.8 |
 anti- LIF antibody |
|||
| LSMab09804 | Lifescience Market | 100 ug | EUR 463.2 |
anti- LIF antibody |
|||
| FNab09804 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against LIF |
|||
Anti-LIF Antibody |
|||
| PB9036 | BosterBio | 100ug/vial | EUR 400.8 |
 Anti-LIF antibody |
|||
| STJ29846 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: The protein encoded by this gene is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. |
|||
Anti-LIF antibody |
|||
| STJ73631 | St John's Laboratory | 100 µg | EUR 430.8 |
Anti-LIF antibody |
|||
| STJ96472 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to LIF. |
|||
 Mouse LIF shRNA Plasmid |
|||
| 20-abx971321 | Abbexa |
|
|
 Mouse LIF ELISA Kit |
|||
| EML0014 | Abclonal | 96Tests | EUR 625.2 |
 Recombinant Mouse LIF Protein |
|||
| R01400-1 | BosterBio | 100ug/vial | EUR 352.8 |
 antibody) Anti-LIF (aa28-39) antibody |
|||
| STJ72919 | St John's Laboratory | 100 µg | EUR 430.8 |
 Polyclonal Goat anti-GST α-form |
|||
| GST-ANTI-1 | Detroit R&D | 50 uL | EUR 336 |
 Polyclonal Goat anti-GST μ-form |
|||
| GST-ANTI-2 | Detroit R&D | 50 uL | EUR 336 |
 Polyclonal Goat anti-GST p-form |
|||
| GST-ANTI-3 | Detroit R&D | 50 uL | EUR 336 |
 LIF Antibody |
|||
| 1-CSB-PA198481 | Cusabio |
|
|
|
Description: A polyclonal antibody against LIF. Recognizes LIF from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:10000, IHC:1:25-1:100 |
|||
LIF Antibody |
|||
| 1-CSB-PA004761 | Cusabio |
|
|
|
Description: A polyclonal antibody against LIF. Recognizes LIF from Human. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000 |
|||
LIF Antibody |
|||
| DF13730 | Affbiotech | 100ul | EUR 420 |
 rHu LIF |
|||
| AK9977-0005 | Akron Biotech | 5µg | Ask for price |
rHu LIF |
|||
| AK9977-0025 | Akron Biotech | 25µg | Ask for price |
rHu LIF |
|||
| AK9977-0100 | Akron Biotech | 100µg | Ask for price |
rHu LIF |
|||
| AK9977-1000 | Akron Biotech | 1mg | Ask for price |
LIF Antibody |
|||
| 1-CSB-PA012928ESR2HU | Cusabio |
|
|
|
Description: A polyclonal antibody against LIF. Recognizes LIF from Human. This antibody is Unconjugated. Tested in the following application: ELISA |
|||
 LIF antibody |
|||
| 70R-51295 | Fitzgerald | 100 ul | EUR 292.8 |
|
Description: Purified Polyclonal LIF antibody |
|||
LIF antibody |
|||
| 70R-6230 | Fitzgerald | 50 ug | EUR 560.4 |
|
Description: Rabbit polyclonal LIF antibody |
|||
 LIF Peptide |
|||
| 43-200P | ProSci | 0.1 mg | EUR 405.6 |
LIF Antibody |
|||
| 5216-100 | Biovision | EUR 379.2 | |
LIF Antibody |
|||
| 5216-30T | Biovision | EUR 175.2 | |
LIF antibody |
|||
| 70R-12299 | Fitzgerald | 100 ug | EUR 483.6 |
|
Description: Rabbit polyclonal LIF antibody |
|||
LIF Antibody |
|||
| 6245-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: LIF Antibody: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation. |
|||
LIF Antibody |
|||
| 6245-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: LIF Antibody: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation. |
|||
LIF Peptide |
|||
| 6245P | ProSci | 0.05 mg | EUR 197.7 |
|
Description: (IN) LIF peptide |
|||
LIF antibody |
|||
| 70R-14100 | Fitzgerald | 100 ug | EUR 386.4 |
|
Description: Affinity purified Rabbit polyclonal LIF antibody |
|||
LIF Antibody |
|||
| 36950-100ul | SAB | 100ul | EUR 302.4 |
 LIF protein |
|||
| 30R-2771 | Fitzgerald | 10 ug | EUR 442.8 |
|
Description: Purified recombinant Human LIF protein |
|||
LIF protein |
|||
| 30R-2772 | Fitzgerald | 10 ug | EUR 586.8 |
|
Description: Purified recombinant Mouse LIF protein |
|||
LIF Antibody |
|||
| 25283-100ul | SAB | 100ul | EUR 468 |
 LIF siRNA |
|||
| 20-abx922546 | Abbexa |
|
|
LIF siRNA |
|||
| 20-abx922547 | Abbexa |
|
|
 LIF, human |
|||
| MO16101 | Neuromics | 100 ug | EUR 825.6 |
 LIF, Human |
|||
| HY-P7049 | MedChemExpress | 10ug | EUR 1920 |
LIF antibody |
|||
| PAab09804 | Lifescience Market | 100 ug | EUR 463.2 |
LIF Antibody |
|||
| F49998-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 165 |
LIF Antibody |
|||
| F49998-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
LIF Antibody |
|||
| R30639 | NSJ Bioreagents | 100 ug | EUR 419 |
LIF Antibody |
|||
| R31467 | NSJ Bioreagents | 100 ug | EUR 419 |
LIF Antibody |
|||
| R36251-100UG | NSJ Bioreagents | 100 ug | EUR 399 |
 Mouse LIF PicoKine ELISA Kit |
|||
| EK0580 | BosterBio | 96 wells | EUR 510 |
|
Description: For quantitative detection of mouse LIF in cell culture supernates, serum and plasma (heparin, EDTA). |
|||
 ELISA kit for Mouse LIF |
|||
| EK5250 | SAB | 96 tests | EUR 663.6 |
|
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse LIF in samples from serum, plasma, tissue homogenates and other biological fluids. |
|||
 Human CellExp? LIF, mouse recombinant |
|||
| 7268-10 | Biovision | EUR 444 | |
 (OKBB00760)) LIF ELISA Kit (Mouse) (OKBB00760) |
|||
| OKBB00760 | Aviva Systems Biology | 96 Wells | EUR 606 |
|
Description: Description of target: Leukemia inhibitory factor, or LIF, is an interleukin 6 class cytokine that affects cell growth by inhibiting differentiation. When LIF levels drop, the cells differentiate. The LIF was mapped gene to 22q11-q12.2 by Southern analysis of a series of mouse/human somatic cell hybrids and by in situ hybridization to the chromosomes of 2 normal males and some individuals with chromosomal rearrangements. The gene maps between the Philadelphia translocation BCR1 and the breakpoint of the translocation in cell line GM2324 at 22q12.2. LIF derives its name from its ability to induce the terminal differentiation of myeloid leukemic cells, thus preventing their continued growth. Other properties attributed to the cytokine include: the growth promotion and cell differentiation of different types of target cells, influence on bone metabolism, cachexia, neural development, embryogenesis and inflammation.;Species reactivity: Mouse;Application: ELISA;Assay info: ;Sensitivity: <10pg/ml |
|||
 (OKEH04045)) LIF ELISA Kit (Mouse) (OKEH04045) |
|||
| OKEH04045 | Aviva Systems Biology | 96 Wells | EUR 652.8 |
|
Description: Description of target: LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes.;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.039 ng/mL |
|||
 LIF, Mouse Recombinant , 1MIU/ml |
|||
| L4500-001 | GenDepot | 1ml | EUR 406.8 |
LIF, Mouse Recombinant , 1MIU/ml |
|||
| L4500-005 | GenDepot | 5x1ml | EUR 1431.6 |
 LIF, Mouse Recombinant , 10MIU/ml |
|||
| L4501-001 | GenDepot | 1ml | EUR 1744.8 |
 (pORF)) Lif ORF Vector (Mouse) (pORF) |
|||
| ORF049145 | ABM | 1.0 ug DNA | EUR 607.2 |
Lif ORF Vector (Mouse) (pORF) |
|||
| ORF049146 | ABM | 1.0 ug DNA | EUR 607.2 |
